30:52
Session 10 - Integrating Sustainability The Next Frontier for Pharma
01:10:43
Session 9 - Panel Discussion Advances in Cleaning Procedures to Minimize Cross Contamination
40:00
Session 8 - Insights from IPA Best Practices Documents
48:49
Session 7 - Achieving Operational Excellence through Continuous Manufacturing
40:08
Session 6 | Revised Schedule M Driving Regulatory Harmonization
59:49
Session 5 Panel - Discussion Strengthening Quality Assurance in Clinical and BA/BE Studies
24:45
Session 1 - Opening Remarks
04:57
Session 1 - Inaugural Address
03:09
Session 1 - Welcome and Context Setting
49:59
Session 4 Strengthening Lifecycle Management Technical & Reguatory Considerations Mahesh Ramanadham
30:09
Session 3 Strategies for Addressing FDA 483 and Warning Letters Guerlain Ulysse
33:29
Session 3 Data Governance Regulatory Expectations and Case Studies Ruth Moore
13:48
Session 1 Opening Remarks from USFDA Gregory Smith
01:06:17
Webinar: Good Engineering Practices - Facilities & Equipment
01:02:07
Session 4: Panel Discussion â Enhancing Current Cybersecurity: Securing the Digital Future
27:44
Session 10: Single Global Development
29:20
Session 10: Regulatory Reforms in India
56:20
Session 13: Panel Discussion - The Biopharma Opportunity, Shaping Future Patient Need
35:50
Session 14: Enhancing Pharmacovigilance: Navigating Compliance and Value for Future
16:01
Session 12: Skilling Institute for Quality and Manufacturing Excellence
39:01
Session 11: Winning the âWar for Talentâ: Advanced Competency Building and Talent Acquisition
49:55
Session 6: Panel Discussion - Modern Control Strategies to Minimize Cross Contamination
10:06
Session 8: Data & Documentation Imperatives of the Future
01:07
Session 9: Opening Remarks
40:45
Session 5: Use of AI in Pharmaceutical Quality and Operations
21:15
Session 3: Introduction to Quality Management Maturity (QMM): Key Expectations from the Industry
01:21:18
Session 1: Inaugural Address
01:11:41
Session 16: CEO Panel Discussion
15:18
Session 1 - Opening Remarks
27:58
Session 8: Data & Documentation Imperatives of the Future
01:13:18
Commercialisation of Cell & Gene Therapy - IPA & Citeline
01:06:04
Panel Discussion - Data Integrity within Context of Quality Culture | 8th Advanced GMP Workshop 2023
35:15
Cross Contamination Control Strategy | 8th Advanced GMP Workshop 2023
49:53
Panel Discussion - Working Towards Ensuring Adequate Drug Supply | 8th Advanced GMP Workshop 2023
35:42
Case Study - Transformation through AI | Dr Rajesh Kuppuswamy | 8th Advanced GMP Workshop 2023
25:02
Case Study - Role of Automation & Digitization in Manufacturing & Quality | Dr Birendra Sing
57:12
Responding to FDA 483 Inspection Observations | Dr Carmelo Rosa | 8th Advanced GMP Workshop 2023
41:06
Harnessing ERP for Enhanced Compliance - Mr Raghuram Janapareddy | 8th Advanced GMP Workshop 2023
12:40
Opening Remarks - Dr Sarah McMullen, US FDA, India Office | 8th Advanced GMP Workshop 2023
03:11
Collaboration between IPA and PCI - Way Forward - Dr Montu Patel | 8th Advanced GMP Workshop 2023
05:15
Current Updates on Regulatory Framework in India - Mr A K Pradhan | 8th Advanced GMP Workshop 2023
14:39
Keynote Address - Ms S Aparna, Secretary - DoP, GOI | 8th Advanced GMP Workshop 2023
04:08
Inaugural Address - Mr Nilesh Gupta, Managing Director, Lupin | 8th Advanced GMP Workshop 2023
04:11
Welcome and Setting Context Mr Sudarshan Jain, IPA | 8th Advanced GMP Workshop 2023
12:30
Opening Address Dr Sarah McMullen Country Director, US FDA Indian Office
18:55
Establishing a Digital Lighthouse Facility - Geena Malhotra - Global CTO, Cipla | 8th GPQS 23
15:39
Dr Patrizia Cavazzoni, Director, CDER, USFDA | 8th GPQS 23 | 22nd June'23
12:31
S Aparna - Secretary, Department of Pharmaceuticals | Government of India - 8th GPQS23 (22.6.23)
02:12:40
CII-IPA webinar on Collaborative Research on Therapeutics
01:17:29
IPA Knowledge Building Webinar: "How robotic solutions can futureproof pharmaceutical production?"
01:02:00
Webinar On Demand: Enhancing Pharma R&D & Innovations through Strategic Partnerships
02:24
IPA Wishes India A #HappyIndepedenceDay
01:00:01
IPA x Informa: Next Gen Pharma - Cell and Gene-Based Therapies
01:59:44
IPA x SSA Business Solutions | Investigation Reviewer Qualification
01:35:51
IPA x DHL Supply Chain | Best-case Practices in Warehousing and Distribution
01:19
7th GPQS 2022: Dr. Douglas Throckmorton, USFDA talks about 'Quality management maturity'
03:46
7th GPQS 2022: Ms. Kristan Callahan talks about 'Importance of considering quality of raw material'
01:45
7th GPQS 2022: Dr. Manisha Shridhar â Regional Advisor, WHO - SEARO
02:48
7th GPQS 2022: Dr. Nivedita Gupta talks about Indiaâs the worldâs pharmacy and vaccine manufacturer
01:02
7th GPQS 2022: Dr. RogĂŠrio Gaspar talks about 'WHO Mission and triple billion objectives'
X
About
The Indian Pharmaceutical Alliance (IPA) was established in the year 1999 in Mumbai. IPA represents research-based National Pharmaceutical Companies in India. It is an alliance of 24 leading Indian pharmaceutical companies, committed to patient care in India and across the world.
The IPA works closely with the Government on policy-related matters and seeks to imbibe the experiences of the generic pharmaceutical industry internationally. It is also partnering with the Government in the evolution of a patent regime and up-gradation of the regulatory regime in India.
Collectively, IPA member companies account for over 85 percent of the private sector investment in pharmaceutical Research & Development. They also contribute to more than 80 percent of the country's exports of drugs & pharmaceuticals.
Community Guidelines: bit.ly/IPAcommunityguidelines
Tags